FierceBiotech9h
Gilead's Daniel O'Day relishes Dietmar Berger reunion as cancer specialist agrees to join from Sanofi
Berger specialized in cancer long before joining Genentech, holding oncology global clinical development roles at Amgen and ...
Novavax Advances Corporate Growth Strategy Through Sanofi Partnership, Including Achievement of First $50 Million Milestone
Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced ...
Sanofi CEO: "AI is a huge opportunity and we can't be deniers"
Sanofi CEO Paul Hudson says, "AI is a huge opportunity, and we can't be deniers." ...
Sanofi's Tolebrutinib Gets FDA Breakthrough Therapy Designation For NrSPMS
French drug major Sanofi (SNY) announced Friday that the U.S. Food and Drug Administration has granted Breakthrough Therapy ...
The Pharma Letter5h
FDA status for Sanofi’s tolebrutinib in non-relapsing secondary progressive MS
The US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to tolebrutinib for the treatment of ...
Monroe County's Sanofi plant fast-tracked for combination COVID/flu vaccine approval
The US Food and Drug Administration(FDA) has granted Fast Track designation to two non-mRNA combination vaccine candidates ...
Novavax advances growth strategy through partnership with Sanofi
Novavax (NVAX) announced progress in Q4 advancing its corporate growth strategy through its partnership with Sanofi (SNY). The company has ...
STAT5d
Sanofi advances a drug for a rare, platelet-destroying disease
A drug developed by Sanofi raised platelet counts and reduced bleeding episodes in patients with a rare autoimmune disorder ...
Daily8h
USFDA grants Breakthrough Therapy designation to Sanofi tolebrutinib for non-relapsing secondary progressive multiple sclerosis
Paris: Sanofi has announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to ...
Sanofi Unveils $1 Billion China Investment to Boost Production
Sanofi SA will invest around 1 billion euros ($1.1 billion) to build a new insulin production base in Beijing, its biggest ...
Sanofi’s Phase III trial of rilzabrutinib for thrombocytopenia meets endpoint
Sanofi has reported that the Phase III LUNA 3 trial of rilzabrutinib for the treatment of persistent or chronic immune ...